Curran Simpson - 02 Jan 2025 Form 4/A - Amendment Insider Report for REGENXBIO Inc. (RGNX)

Role: Chief Executive Officer, Director
Signature: /s/ Patrick J. Christmas as attorney-in-fact
Issuer symbol: RGNX
Transactions as of: 02 Jan 2025
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 14 Jan 2025, 17:19:54 UTC
Date Of Original Report: 06 Jan 2025
Previous filing: 05 Aug 2024
Next filing: 03 Jul 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RGNX	Stock Options (Right to buy)	Award	$0	+478,606		$0.000000	478,606	02 Jan 2025	Common Stock	478,606	$7.86	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2026 while the optionee provides continuous service to the Issuer.

Remarks:

The original Form 4, filed on January 6, 2025, is being amended by this Form 4 amendment solely to correct a share calculation error on the part of the Issuer, which misreported the amount of stock options granted to the reporting person as 476,606.